Histogenics (HSGX) Misses Q4 EPS by 18c
Tweet
Share
E-mailGet Alerts HSGX Hot Sheet
Join SI Premium – FREE
Histogenics (NASDAQ: HSGX) reported Q4 EPS of ($0.63), $0.18 worse than the analyst estimate of ($0.45).
For earnings history and earnings-related data on Histogenics (HSGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brunswick (BC) Reports In-Line Q1 EPS, provides guidance
- West Pharma (WST) Tops Q1 EPS by 26c, provides guidance
- Dover Corp. (DOV) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
